Vaccine development and testing, containment level 2 and 3 infectious disease research, large animal models of disease, preclinical trials, regulatory trials
VIDO-InterVac is one of Canada’s premier research institutes, with over 40 years of experience in infectious disease research and vaccine development for animals and humans. VIDO-InterVac has more than 150 personnel and some of the world’s most advanced containment infrastructure, including containment level 2 and level 3 animal housing and laboratories, a select agent lab, an aerobiology challenge unit, and a 160-acre containment level 2 research station. The unique $140-million large animal containment level 3 laboratory (the International Vaccine Centre or InterVac) became operational in 2013. VIDO-InterVac can complete multiple stages of vaccine development including pre-clinical trials for human vaccines and full regulatory and efficacy trials for animal vaccines.
Pathogenomics, proteomics, metabolomics, kinomics, antigen identification, vaccine development, vaccine formulation and delivery, animal disease models (containment 2 and 3), preclinical vaccine testing (human), regulatory vaccine testing (animals)
- Agriculture, animal science and food
- Defence and security industries
- Fisheries and aquaculture
- Healthcare and social services
Specialized labs and equipment
|
Specialized lab |
Equipment |
Function |
|---|---|---|
|
VIDO-InterVac
|
Containment Level 2 (CL2) |
100,000 square feet of level 2 lab space and additional 20,000 square feet of level 2 animal isolation |
|
VIDO-InterVac |
Containment Level 3 (CL3)
|
18 CL3 animal suites (including aerobiology challenge units) that can accommodate most animal species. 6 CL3 laboratories. |
|
Research station |
160-acre Research Station |
Research station certified to containment level 2 able to conduct large animal studies including efficacy trials on horses and cattle |
|
VIDO-InterVac – CL3 aerobiology laboratory |
Madison Chamber, fully suited |
Fully suited laboratory for aerobiology challenge experiments including Canada’s only Madison chamber for aerobiology challenge experiments |
|
VIDO-InterVac – select agent laboratory |
Class 3 Glovebox |
Provides infrastructure required to work with select agents as classified by the Federal Select Agent Program in the United States |
Private and public sector research partners
- AbCelex Technologies
- Alberta Research Chemicals
- AnGes MG
- Boehringer Ingelheim
- Canadian Swine Health Board
- Elanco
- Guangzhou Institute of Respiratory Disease
- Guangzhou Yuanbo Medical Technology Co.
- Huvepharma
- Intervet Canada
- Kamada
- Konkuk University
- Lumen Associates
- Medicago
- Merck Animal Health
- Merial
- Ohio State University
- Phileo-Lesaffre Animal Care
- South China Vaccine Corporation
- SterileCare
- University of Alberta
- University of British Columbia
- University of Calgary
Additional information
|
Title |
URL |
|---|---|
|
University of Saskatchewan gets major federal boost for isotope and vaccine production, water research |
https://news.usask.ca/media-release-pages/2018/u-of-s-gets-major-federal-boost-for-isotope-and-vacc… |
|
VIDO-InterVac helping to fight Zika virus |
|
|
University of Saskatchewan VIDO-InterVac develops vaccine for devastating pig virus |
https://news.usask.ca/media-release-pages/2016/u-of-s-vido-intervac-develops-vaccine-for-devastatin… |
|
Funding awarded to develop vaccines for bovine tuberculosis and Johne’s disease |
http://vido.org/news/funding-awarded-to-develop-vaccines-for-bovine-tuberculosis-and-johne’s-disease |
|
Government of Canada announces funding to enhance influenza vaccine research and development |
https://www.canada.ca/en/news/archive/2015/05/government-canada-announces-funding-enhance-influenza… |
|
Saving Lives Through Vaccine Research |
|
|
University of Saskatchewan International Vaccine Centre Celebrates Grand Opening |
http://www.vido.org/news/u-of-s-international-vaccine-centre-celebrates-grand-opening |